Psoriatic arthritis

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Retrieved on: 
Mittwoch, September 6, 2023
Psoriatic arthritis, Q&A, Capital market, Skin, Innovation, ARGO, Associate, Harvard Medical School, HS, Hidradenitis suppurativa, Division, DSM-IV codes, CEST, Webcast, MIRA, Moonlake, MMSc, Inflammation, Pharmaceutical industry, Dermatology, Rheumatology, Brigham, MD

ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Day for investors and analysts on Monday, September 11.

Key Points: 
  • ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Day for investors and analysts on Monday, September 11.
  • The live webcast will be viewable from 11:30 am – 13:00 pm EDT/16:30 pm – 18:00 BST/17:30 – 19:00 pm CEST.
  • Registration for the webcast is open and accessible online here .
  • The MoonLake team will discuss the evolving psoriatic arthritis (PsA) market and expectations ahead of the top-line 12-week results from the Phase 2 ARGO trial which is expected in the first half of November 2023.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Montag, August 14, 2023
IPO, Axial spondyloarthritis, IV, Spermatogenesis, Nektar Therapeutics, Doctor of Philosophy, Pain, Graves' ophthalmopathy, Psoriatic arthritis, Dermatology, Teprotumumab, MD, Patient, Randomized controlled trial, Prurigo nodularis, DMC, Disease, Tissue, SLRN, Disability, Human, IL-17A, Data, Hearing, Uveitis, Rheumatology, Growth, FDA, Safety, D, Secukinumab, Neutropenia, Exercise, POC, Eosinophilic esophagitis, Allergy, B cell, AAD, Webcast, CFO, Enthesitis, LOS, Research, Hives, Therapy, Inflammation, Huber loss, CU, Data monitoring committee, TED, Pharmaceutical industry, Vaccine, Management, Rare-earth element, HS, Part, Hidradenitis suppurativa

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Donnerstag, August 10, 2023
Inflammation, Psoriasis Area and Severity Index, Calendar, Capital market, Medical college, American Academy, ARGO, Guggenheim, IL-17A, Antibody, Hidradenitis suppurativa, Patient, Physician, Medical College of Wisconsin, PASI, Growth, MIRA, Research, Moonlake, Conference, Skin, Safety, Pharmaceutical industry, Payment card, Security (finance), Rare-earth element, Dermatology, HS, Psoriatic arthritis

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “This quarter has been transformational for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “This quarter has been transformational for MoonLake.
  • Second Quarter 2023 Financial Highlights:
    On June 30, 2023, MoonLake closed a public offering of 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per Share.
  • Research and development expenses for the quarter ended June 30, 2023, were $8.7 million, compared to $7.4 million in the previous quarter.
  • General and administrative expenses for the quarter ended June 30, 2023, were $4.5 million, compared to $5.5 million in the previous quarter.

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, August 9, 2023
Insurance, Communication, CFA, Cystic fibrosis, Data analysis, Patient, Cystic Fibrosis Foundation, Disease, NYSE, PIPE, Policy, Pharmacokinetics, CFU, Pseudomonas aeruginosa, Corporation, Bacteria, Treasurer, FDA, CF, Conference, Safety, International, Professional corporation, ECFC, Psoriatic arthritis, Mortality, Research, Therapy, FEV1, Sputum, Workforce, Drug development, Clinical trial, Urinary tract infection, Fast Track, Part, Plasma protein binding, NESS, Phage therapy, Poster, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Biogen, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.
  • “Our BX004 clinical program in cystic fibrosis (“CF”) continues to build significant momentum,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Net loss for the second quarter of 2023 was $6.4 million, compared to $7.5 million for the same period in 2022.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter of 2023.

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Montag, August 7, 2023
Janus, PK, Psoriatic arthritis, EPI, RA, PD, Therapy, Half-life, Chapter 11, Title 11, United States Code, JAK, Health, Pharmacokinetics, Atopic dermatitis, Methotrexate, G&A, MK2, Washington University in St. Louis, Sale, Ulcerative colitis, Plasma, ACRS, ATM, Lilly, Patient, Collection, Rheumatoid arthritis, R, Research, AD, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency, Video game, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2023 and provided a corporate update.

Key Points: 
  • Aclaris continues to expect topline data in the fourth quarter of 2023.
  • Aclaris continues to expect topline data in the second half of 2023.
  • Net loss was $29.6 million for the second quarter of 2023 compared to $20.5 million for the second quarter of 2022.
  • Total revenue was $1.9 million for the second quarter of 2023 compared to $1.5 million for the second quarter of 2022.

Biologics and Targeted Therapies Revolutionize Psoriatic Arthritis Treatment: Market Analysis and Global Opportunity Assessment - ResearchAndMarkets.com

Retrieved on: 
Mittwoch, August 2, 2023
Health, Other Health, Disease-modifying antirheumatic drug, Arthralgia, Psoriatic arthritis, Inflammation, Psoriasis, Route, Administration, Swelling, Nonsteroidal anti-inflammatory drug, OTC, Route of administration, Diagnosis, Skin, Geography, Pharmaceutical industry, Health insurance

The "Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • PsA is a chronic inflammatory arthritis that affects individuals with psoriasis, a skin condition characterized by red, scaly patches on the skin.
  • The psoriatic arthritis treatment market has witnessed growth due to increased awareness campaigns, educational initiatives, and advancements in diagnostic techniques, leading to early detection and diagnosis of PsA.
  • The psoriatic arthritis treatment market is segmented based on drug type, type, route of administration, and geography.

HSS Achieves Record 14th Consecutive National No. 1 Ranking in Orthopedics by U.S. News & World Report

Retrieved on: 
Dienstag, August 1, 2023
American Hospital Association, Human, Osteoarthritis, Psoriatic arthritis, US Youth Soccer National Championships, Evidence-based medicine, Centers for Medicare & Medicaid Services, Elective surgery, Culture, National Basketball Players Association, Hospital, Infection, Nursing, Scleroderma, MBA, Pickleball, Research, Lupus, American Animal Hospital Association, Doctor of Philosophy, Neck, The Internationale, Rheumatoid arthritis, Brooklyn Nets, Global Coalition Against Pneumonia, Pain, Medicare, Hospital for Special Surgery, Team physician, MD, Patient, Division, Medical Center, HSS, Joint, Health, New York Red Bulls, News, Safety, New York Road Runners, Health care, Rheumatology, U.S. News & World Report, New York Mets

NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Hospital for Special Surgery (HSS), has been ranked the No. 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No. 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis. 

Key Points: 
  • 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No.
  • 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis.
  • HSS maintains the lowest readmission rates for orthopedics in the nation, and among the lowest rates for infections and complications.
  • * Copyright © 2023 U.S. News & World Report, L.P. Data reprinted with permission from U.S. News.

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts  

Retrieved on: 
Dienstag, Juli 25, 2023
ACR, Psoriasis Area and Severity Index, Disease, Arm, Inflammation, Psoriatic arthritis, Capital market, Enthesitis, Clinical trial, Adalimumab, American College of Rheumatology, Hope, ARGO, Antibody, IL-17A, Doctor of Philosophy, Psoriasis, HS, Hidradenitis suppurativa, Patient, Physician, CEST, Webcast, Joint, PASI, MIRA, R, American College, Moonlake, FDA, Conference, Skin, Safety, Pharmaceutical industry, Cryptocurrency, Vaccine

MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023.

Key Points: 
  • MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023.
  • Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “ARGO is MoonLake’s second trial to have achieved faster completion of recruitment and randomization than expected.
  • Reaching this stage well ahead of schedule for active psoriatic arthritis is an encouraging reflection of the interest in our clinical development programs.
  • The trial also includes adalimumab, the current standard of care for PsA, as an active reference arm.

EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar

Retrieved on: 
Montag, Juli 17, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Psoriasis Area and Severity Index, Intas Pharmaceuticals, Psoriatic arthritis, Partnership, CET, Ustekinumab, CSO, IQVIA, Dong Jiahong, Meiji, Marketing, Ulcerative colitis, Psoriasis, EMA, European Medicines Agency, Patient, PASI, Marketing Authorisation Application, MAA, Donga, III, MMA, Pharmaceutical industry, EU, Accord

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).

Key Points: 
  • Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).
  • Accord , a wholly owned subsidiary of Intas Pharmaceuticals Ltd, submitted the MAA to EMA on June 23rd, and the EMA accepted the MMA submission on July 14th in CET.
  • The MAA submission is based on the results of an extensive analytical similarity assessment of DMB-3115 with that US and EU-sourced STELARA using current ‘state-of-the-art’ methods.
  • The MAA submission also comprised the results from the phase III multi-regional clinical trials in patients with plaque psoriasis (NCT04785326).

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Retrieved on: 
Samstag, Juli 1, 2023
Crohn's & Colitis Foundation, National Psoriasis Foundation, Psoriatic arthritis, Interchangeability, Arthritis Foundation, Food and Drug Administration, Dermatology, Quality of life, American Academy, Colitis, Psoriasis, Crohn's disease, Boehringer Ingelheim, Patient, Risk, Phase, FDA, Health, Safety, Food, Management of Crohn's disease, Rheumatoid arthritis, Disease, Generic drug, Pharmaceutical industry, Adalimumab

Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Key Points: 
  • Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.
  • "Cyltezo is the first and only FDA-approved Interchangeable biosimilar to Humira® that is available to the millions of people in the U.S. living with certain chronic inflammatory diseases," said Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim.
  • An Interchangeable biosimilar must first meet the high FDA standards of a biosimilar.
  • "For many people living with plaque psoriasis or psoriatic arthritis, finding effective relief from symptoms can be a daily struggle.